Obesity has impacts on cardiovascular disease outcomes through increased risk of coronary artery disease, heart failure (more prominent with preserved ejection fraction), cardiac arrhythmias (most significantly atrial fibrillation), sudden death, and venous thromboembolism [7]
Fact: More is not always better
They have been shown to reduce the risk of adverse cardiovascular and renal outcomes compared with some other diabetes medications relevant given how common these conditions are in older adults with diabetes
Ans : Generally safe, but individuals with specific medical conditions (like G6PD deficiency) should consult a doctor before starting
Glucagon is also involved in acutely regulating glucose homeostasis and administration of pharmacological doses of glucagon in animal models for diabetes or obesity has demonstrated regulatory effects on lipid metabolism, energy expenditure, and food intake ( The GLP-1/glucagon agonist cotadutide (MEDI0382) is the compound of this dual-receptor agonist class that is the most advanced in clinical development
doi:10.3390/biomedicines9060609 Hsieh MJ, Lee CH, Chueh HY, et al
